Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Growth · Rbb

Emerald Growth Fund Class A (HSPGX)

Ticker HSPGX · Since 1992-10-01 · · Holdings as of Jul 31, 2026

Expense ratio
0.95%$95/yr per $10k
5-yr return
+6.7%annualized
1-yr return
+25.5%as of Dec 2025
Net assets
$1.5Ball share classes
Holdings
132

Bottom line

Is HSPGX a good fund? The bottom line

HSPGX is the Class A share class of Emerald Growth Fund, an actively managed large growth mutual fund from Rbb.

It charges 0.95% — about $95 a year on every $10,000 invested, more expensive than 58% of large growth funds we track.

It returned +25.5% over one year, +6.7% a year over five years, +11.8% a year over ten (as of Dec 31, 2025, per its prospectus).

With $1.5 billion in net assets and 132 holdings, its largest position is F/m Emerald Life Sciences Inno (6.1%) and the top 10 make up 21.4% of the portfolio.

This share class carries a front-end sales charge of up to 4.75%; a no-load class or ETF alternative can avoid it.

What to watch

  • 5-year return in the bottom quarter of its category
  • Front-end sales load up to 4.75%
  • 12b-1 marketing fee of 0.35% a year

Updated Nov 19, 2026

What HSPGX invests in

Emerald Growth Fund (the Fund) seeks long-term growth through capital appreciation.

The Fund has adopted an investment policy that it will, under normal conditions, invest at least 80% of the value of its assets (net assets plus the amount of any borrowings for investment purposes) in equity securities of U.S. and foreign companies, principally common stocks and preferred stocks, identified by the Adviser as having growth characteristics. In identifying investments with growth characteristics, the Adviser utilizes a fundamental approach to choosing securities: the research staff of Emerald conducts company-specific research analysis, taking into account a companys revenue and earnings growth rates and the financial, operating, and market characteristics that distinguish a company from other companies. The Funds policy to invest at least 80% of its assets in such a manner is non-fundamental, which means that it may be changed without shareholder approval. Shareholders…

From the fund's prospectus (filed Sep 8, 2026).

HSPGX performance

Fund calendar-year total returns, 2015–2025 2015: +1.0%; 2016: +10.5%; 2017: +27.7%; 2018: −11.9%; 2019: +28.3%; 2020: +38.4%; 2021: +3.7%; 2022: −24.7%; 2023: +18.7%; 2024: +19.1%; 2025: +31.7% +1% 2015 +11% 2016 +28% 2017 −12% 2018 +28% 2019 +38% 2020 +4% 2021 −25% 2022 +19% 2023 +19% 2024 +32% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
HSPGX+25.5%+6.7%+11.8%
Large Growth median+15.2%+11.0%+14.2%

Source: Fund prospectus, as of Dec 31, 2025

Full HSPGX performance history →

What HSPGX costs

On a $10,000 investment, HSPGX's 0.95% expense ratio costs about $95 a year. The prospectus estimates $1,617 in total costs over 10 years (assuming 5% annual returns). The median large growth fund charges 0.87%.

See the full HSPGX fee table →

HSPGX top 10 holdings

#Holding% of fund
1F/m Emerald Life Sciences Inno LFSC6.14%
2U.S. Bank Money Market Deposit Account1.98%
3AAR Corp AIR1.95%
4InterDigital Inc IDCC1.83%
5Travere Therapeutics Inc TVTX1.69%
6VSE Corp VSEC1.68%
7Mercury Systems Inc MRCY1.63%
8Corcept Therapeutics Inc CORT1.54%
9ESCO Technologies Inc ESE1.51%
10Sensient Technologies Corp SXT1.47%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 21.4% of the fund. See all top 25 holdings and asset mix →

Alternatives to HSPGX

More funds like HSPGX →

HSPGX FAQ

What is the expense ratio of HSPGX?
HSPGX's expense ratio is 0.95%, which works out to about $95 a year for every $10,000 invested. The prospectus estimates total costs of $1,617 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is HSPGX a good investment?
It depends on your goals, but the data points to: 5-year return in the bottom quarter of its category; front-end sales load up to 4.75%; 12b-1 marketing fee of 0.35% a year. This is general information, not personalized advice.
What does HSPGX hold?
HSPGX's largest holdings are F/m Emerald Life Sciences Inno (6.1%), U.S. Bank Money Market Deposit Account (2.0%), AAR Corp (1.9%), InterDigital Inc (1.8%), Travere Therapeutics Inc (1.7%). It holds 132 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is HSPGX's 5-year return?
HSPGX returned +6.7% a year over the five years ending Dec 31, 2025, and +11.8% a year over ten years. Past performance does not guarantee future results.
Does HSPGX have a sales load?
Yes. HSPGX has a maximum front-end sales charge of 4.75%.
Who manages HSPGX?
HSPGX is offered by Rbb through Rbb Fund, Inc..